A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.

Launched by SANOFI · Feb 23, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the safety and effectiveness of new vaccines designed to protect against several respiratory viruses, including influenza and others like respiratory syncytial virus (RSV) and parainfluenza. The trial is open to healthy adults aged 18 to 49 years. Participants will receive one injection of a vaccine and will be closely monitored for any side effects or reactions.

To be eligible for the study, participants must not be pregnant or breastfeeding and should agree to use effective birth control if they are of childbearing potential. Throughout the study, participants will keep a diary to track their health, including any reactions at the injection site and their daily temperature. This information will help researchers understand how well the vaccines work and their safety. Overall, this trial is an important step in developing vaccines to help protect against respiratory illnesses.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 18 to 49 years on the day of inclusion
• * A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:
• • Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, or surgically sterile OR
• • Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to study intervention administration until at least 4 weeks after study intervention administration.
• Exclusion Criteria:
• • - Any medical condition or circumstance which, in the opinion of the investigator, might interfere with the evaluation of the study objectives
• • Note: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.